iBio, Inc. (NYSE:IBIO) CFO Acquires $24,999.52 in Stock

iBio, Inc. (NYSE:IBIO) CFO Felipe Duran acquired 9,191 shares of the business’s stock in a transaction dated Friday, January 10th. The shares were bought at an average cost of $2.72 per share, for a total transaction of $24,999.52. Following the transaction, the chief financial officer now directly owns 11,139 shares in the company, valued at approximately $30,298.08. This represents a 471.82 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

iBio Price Performance

IBIO stock opened at $2.85 on Thursday. The stock’s 50 day simple moving average is $2.51 and its 200 day simple moving average is $2.29. The company has a quick ratio of 3.37, a current ratio of 3.37 and a debt-to-equity ratio of 0.04. iBio, Inc. has a fifty-two week low of $1.02 and a fifty-two week high of $4.98.

iBio (NYSE:IBIO) last issued its earnings results on Tuesday, November 12th. The company reported ($0.46) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.46). Equities research analysts forecast that iBio, Inc. will post -1.74 EPS for the current fiscal year.

About iBio

iBio, Inc, a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.